Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies?

AIDS

Volumn 28, Issue 10, 2014, Pages 1379-1391

  Gelu Simeon, Moana ^a,b,h   Sobesky, Rodolphe ^a,b,c,d   Haïm Boukobza, Stéphanie ^a,b,c   Ostos, Marita ^a,b   Teicher, Elina ^a,b,c,e   Fontaine, Hélène ^f   Salmon Ceron, Dominique ^f   Meyer, Laurence ^e   Trinchet, Jean Claude ^g   Paule, Bernard ^a,b   Samuel, Didier ^a,b,c,d   Lewin, Maïté ^a,b,c,d   Duclos Vallée, Jean Charles ^a,b,c,d  

^a HÔPITAL PAUL BROUSSE   (France)

^b DHU Hepatinov ^*  (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e BICÊTRE HOSPITAL   (France)

^f Institut Cochin   (France)

^g UNIVERSITÉ PARIS 13   (France)

^h Centre Hospitalier Universitaire Pointe a Pitre   (Guadeloupe)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocarcinogenesis; Hepatocellular carcinoma; HIV; Prognostic factors

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN; SORAFENIB;

ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SCREENING; CHRONIC LIVER DISEASE; COMORBIDITY; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; POLICY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SURVIVAL; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEALTH CARE POLICY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; INCIDENCE; MASS SCREENING; PROCEDURES;

CARCINOMA, HEPATOCELLULAR; HEALTH POLICY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MASS SCREENING;

EID: 84902277788     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000300     Document Type: Review

References (110)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-2917.
2. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992- 2008. Hepatology 2012; 55:476-482.
3. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943.
4. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48:137-145.
5. Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2012; 118:6226-6233.
6. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57:249-257.
7. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
8. Buffet-Janvresse C, Peigue-Lafeuille H, Benichou J, Vabret A, Branger M, Trimoulet P, et al. HIV and HCV co-infection: situation at six French university hospitals in the year 2000. J Med Virol 2003; 69:7-17.
9. Larsen C, Pialoux G, Salmon D, Antona D, Le Strat Y, Piroth L, et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill 2008; 13. pii: 18888.
10. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380:1840-1850.
11. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and metaanalysis. Int J Infect Dis 2010; 14:1024-1031.
12. Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011; 25:1987-1992.
13. Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008; 47:94-101.
14. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012; 61 (Suppl 1):i47-i58.
15. Pineda JA, Aguilar-Guisado M, Rivero A, Girón-González JA, Ruiz-Morales J, Merino D, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009; 49:1274-1282.
16. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
17. Martel-Laferriére V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 2014; 15:108-115.
18. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-1273.
19. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol 2009; 50:736-745.
20. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot- Martin I, Rabaud C, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virusinfected patients. J Clin Oncol 2003; 21:3447-3453.
21. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski J-P, Ganne N, Hillon P, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48:200-207.
22. Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-130.
23. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The Mortalité 2000 and 2005 surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
24. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIVinfected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736.
25. Petoumenos K, Law MG. Risk factors and causes of death in the Australian HIV Observational Database. Sex Health 2006; 3:103-112.
26. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, et al. Liver-related mortality in human-immunodeficiencyvirus- infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14:183-188.
27. Weber R, Sabin CA, Friis-Muller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
28. Lemoine M, Ingiliz P. Liver injury in HIV monoinfected patients: should we turn a blind eye to it? Clin Res Hepatol Gastroenterol 2012; 36:441-447.
29. Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis 2012; 25:10-16.
30. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485-1491.
31. Merchante N, Merino E, López-Aldeguer J, Jover F, Delgado- Fernández M, Galindo MJ, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013; 56:143-150.
32. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48:353-367.
33. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164:2349-2354.
34. Garcá-Garcá JA, Romero-Gómez M, Girón- González JA, Rivera-Irigoin R, Torre-Cisneros J, Montero JL, et al. Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis. AIDS Res Hum Retroviruses 2006; 22:1236-1241.
35. McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006; 24:5005-5009.
36. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
37. Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS 2007; 21:771-774.
38. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35:14-20.
39. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126:102-110.
40. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIVco-infection. Antiviral Res 2010; 85:303-315.
41. Konopnicki D, Mocroft A, De Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
42. Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527-537.
43. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
44. Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
45. Liaw Y-F. Impact of therapy on the outcome of chronic hepatitis B. Liver Int 2013; 33 (Suppl 1):111-115.
46. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011; 6:478-482.
47. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009; 83:7366-7374.
48. Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, et al. Evolution of hepatitis B serological markers in HIVinfected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45:1221-1229.
49. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
50. Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer 2012; 1:226-237.
51. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra91.
52. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226-233.
53. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterialDNAcorrelate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-1185.
54. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44 (Suppl 1):S65-S70.
55. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, et al. Comparison of HCV-specific intrahepatic CD4R T cells in HIV/HCV versus HCV. Hepatology 2004; 40:125-132.
56. Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010; 52:612-622.
57. Häm-Boukobza S, Balabanian K, Teicher E, Bourgeade M, Perlemuter G, Roque-Afonso A-M, et al. Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients. J Hepatol 2013; 59:613-615.
58. Ochoa-Callejero L, Pérez-Martínez L, Rubio-Mediavilla S, Oteo JA, Martínez A, Blanco JR. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One 2013; 8:e53992.
59. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. Cold Spring Harb Perspect Med 2012; 2. pii: a006866.
60. Balasubramanian A, Ganju RK, Groopman JE. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. J Infect Dis 2006; 194:670-681.
61. Bettaccini AA, Baj A, Accolla RS, Basolo F, Toniolo AQ. Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes. BMC Microbiol 2005; 5:20.
62. Cromlish JA. Hepatitis B virus-induced hepatocellular carcinoma: possible roles for HBx. Trends Microbiol 1996; 4:270-274.
63. Barak O, Aronheim A, Shaul Y. HBV X protein targets HIV Tatbinding protein 1. Virology 2001; 283:110-120.
64. Benegiamo G, Vinciguerra M, Guarnieri V, Niro GA, Andriulli A, Pazienza V. Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells. FEBS Lett 2013; 587:1424-1428.
65. Sengupta S, Powell E, Kong L, Blackard JT. Effects of HCV on basal and tat-induced HIV LTR activation. PLoS One 2013; 8:e64956.
66. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25:3834-3847.
67. Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 2008; 38:1-26.
68. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
69. Triboulet R, Mari B, Lin Y-L, Chable-Bessia C, Bennasser Y, Lebrigand K, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007; 315:1579-1582.
70. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med 2010; 16:257-267.
71. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012; 143:550-563.
72. Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther 2013; 6:1167-1178.
73. Thibault PA, Wilson JA. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: inhibiting the virus and altering the host. Pharmacol Res 2013; 75:48-59.
74. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and nontumorous tissues. Oncogene 2006; 25:2537-2545.
75. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterialDNAcorrelate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-1185.
76. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012; 61:1600-1609.
77. Lemoine M, Barbu V, Girard PM, Kim M, Bastard J-P, Wendum D, et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006; 20:387-395.
78. Lemoine M, Capeau J, Serfaty L. PPAR and liver injury in HIVinfected patients. PPAR Res 2009; 2009:906167.
79. Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010; 16:218-229.
80. Liu H-Y, Han J, Cao SY, Hong T, Zhuo D, Shi J, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem 2009; 284:31484-31492.
81. Parker RA, Flint OP, Mulvey R, Elosua C, Wang F, Fenderson W, et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 2005; 67:1909-1919.
82. Kim AY, Chung RT. Coinfection with HIV-1 and HCV - a onetwo punch. Gastroenterology 2009; 137:795-814.
83. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285-2293.
84. Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, et al. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol 2012; 36:214-221.
85. Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist 2011; 16:1258-1269.
86. Lim C, Goutte N, Gervais A, Vullierme M-P, Valla DC, Degos F, et al. Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma. J Acquir Immune Defic Syndr 2012; 61:581-587.
87. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022.
88. Jelic S, Sotiropoulos GC, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5):v59-64.
89. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54:1987-1997.
90. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/ AIDS. Clin Infect Dis 2012; 54:1465-1472.
91. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.
92. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88.
93. Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis 2012; 54 (Suppl 4):S245-S249.
94. Lacombe K, Boyd A, Desvarieux M, Serfaty L, Bonnord P, Gozlan J, et al. Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus. AIDS 2007; 21:2546-2549.
95. Boyd A, Miailhes P, Brichler S, Scholtés C, Maylin S, Delaugerre C, et al. Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. AIDS Res Hum Retroviruses 2013; 29:1535-1540.
96. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
97. De Nardo P, Viscione M, Corpolongo A, Bellagamba R, Vennarecci G, Ettorre GM, et al. Treatment of recurrent hepatocellular carcinoma with sorafenib in a HIV/HCV coinfected patient in HAART: a case report. Infect Agents Cancer 2012; 7:15.
98. Perboni G, Costa P, Fibbia GC, Morandini B, Scalzini A, Tagliani A, et al. Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. Oncologist 2010; 15:142-145.
99. Ozenne V, Gervais A, Peytavin G, Castelnau C, Valla DC, Degos F. Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report. Hepatogastroenterology 2011; 58:161-162.
100. Berretta M, Di Benedetto F, Dal Maso L, Cacopardo B, Nasti G, Facchini G, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anticancer Drugs 2013; 24:212-218.
101. Esposito V, Verdina A, Manente L, Spugnini EP, Viglietti R, Parrella R, et al. Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J Cell Physiol 2013; 228:640-645.
102. Vibert E, Duclos-Vallée J-C, Ghigna M-R, Hoti E, Salloum C, Guettier C, et al. Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology 2011; 53:475-482.
103. Samuel D, Weber R, Stock P, Duclos-Vallée J-C, Terrault N. Are HIV-infected patients candidates for liver transplantation? J Hepatol 2008; 48:697-707.
104. Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188:1412-1420.
105. Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001; 72:1684-1688.
106. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143:986-994e3; quiz e14-15.
107. Hughes CA, Shafran SD. Treatment of hepatitis C in HIVcoinfected patients. Ann Pharmacother 2006; 40:479-489; quiz 582-583.
108. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, et al., Kyushu University Liver Disease Study (KULDS) Group. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58:495-501.
109. Merchante N, Merino E, Rodríguez-Arrondo F, Tural C, Muñoz J, Delgado-Fernández M, et al. HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. AIDS 2014; 28:41-47.
110. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58:98-107.